As the global COVID-19 pandemic has progressed, so too have efforts to develop, manufacture, and secure the supply of potentially effective vaccines. At the time of writing, more than 45 vaccine candidates have entered clinical development, with several front-runners including Pfizer-BioNTech well positioned to begin delivering vaccines in the near future. But procuring bodies such as governments and supranational organizations face many challenges in getting vaccines in the hands of patients.
